Mode
Text Size
Log in / Sign up

Patient Questions

Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.

Cardiology

Does a natriuresis-guided diuretic protocol shorten hospital stays for acute decompensated heart failure?

Evidence is mixed: one meta-analysis found natriuresis-guided protocols shortened hospital stays by about 1 day, but another found no significant difference.

Cardiology

Is Xarelto approved to prevent strokes in patients with Nonvalvular Atrial Fibrillation?

Yes, Xarelto (rivaroxaban) is FDA-approved for stroke prevention in nonvalvular atrial fibrillation, based on the ROCKET-AF trial showing it is noninferior to warfarin with a…

Cardiology

Does left atrial appendage closure cause less bleeding than NOACs for Nonvalvular Atrial Fibrillation?

Yes, left atrial appendage closure (LAAC) causes significantly less non-procedural bleeding than NOACs in patients with nonvalvular atrial fibrillation, based on recent trials.

Cardiology

Are there sex differences in stroke outcomes for people with Nonvalvular Atrial Fibrillation?

Yes, sex differences exist: women with NVAF-related stroke tend to have worse short-term outcomes, but after adjusting for age and other factors, their long-term mortality risk…

Cardiology

Is left atrial appendage occlusion better than warfarin for Nonvalvular Atrial Fibrillation mortality?

Yes, left atrial appendage occlusion (LAAO) is associated with lower all-cause mortality compared to warfarin in patients with nonvalvular atrial fibrillation, based on network…

Cardiology

Can a sirolimus-eluting iron bioresorbable scaffold treat coronary artery disease patients with myocardial ischemia?

A 2024 trial found that a sirolimus-eluting iron bioresorbable scaffold did not perform as well as standard metallic stents for treating coronary artery disease in patients with…

Cardiology

Does a sirolimus-eluting iron scaffold cause more late lumen loss than everolimus stents for myocardial ischemia?

Yes, the sirolimus-eluting iron scaffold (IBS) showed higher late lumen loss than the everolimus-eluting stent at 2 years in the IRONMAN-II trial.

Cardiology

Are there specific animal models used to study cardiometabolic disease induction methods?

Researchers use mice and rats with diet-induced obesity, heart attacks, or specific genetic changes to study cardiometabolic diseases like heart failure and diabetes.

Cardiology

How do researchers induce cardiometabolic disease in mice for spatial transcriptomics studies?

Researchers induce cardiometabolic disease in mice primarily by feeding them a high-fat diet, often combined with chemical treatments like VCD to mimic postmenopausal states.

Cardiology

Can the ALBI score predict how long I might live after NSTEMI?

Yes, the ALBI score can predict mortality risk after NSTEMI, with higher scores indicating a significantly higher risk of death.

Cardiology

Can ginsenoside CK help protect my heart from arrhythmias?

Research suggests ginsenoside CK has antiarrhythmic potential and can protect the heart from injury in models of ischemia, sepsis, and chemotherapy, though clinical use is still…

Cardiology

Can colchicine help reduce plaque in coronary atherosclerosis?

Yes, colchicine can help reduce plaque in coronary atherosclerosis by lowering inflammation, though evidence on direct plaque volume reduction is mixed.

Cardiology

What is the practical framework for treating coronary atherosclerosis?

Treating coronary atherosclerosis now requires a dual-axis framework that lowers lipids and targets inflammation, moving beyond just fixing blocked arteries to stabilizing the…

Cardiology

How do combined lipid and anti-inflammatory therapies work for coronary atherosclerosis?

Combined therapies work by lowering LDL cholesterol while simultaneously reducing the chronic inflammation that drives plaque growth and rupture.

Cardiology

Can echocardiographic strain imaging find cardiac amyloidosis in patients with left ventricular hypertrophy?

Yes, echocardiographic strain imaging, especially the apical sparing ratio, can help detect cardiac amyloidosis in patients with left ventricular hypertrophy, but its accuracy is…

Cardiology

Will intensive medical treatment reduce my major adverse cardiovascular events?

For women with ANOCA/INOCA, intensive medical treatment did not reduce major adverse cardiovascular events over 2.5 years compared to usual care.

Cardiology

Does having ANCA-associated vasculitis increase my risk of heart problems and death?

Having ANCA-associated vasculitis significantly increases your risk of heart attacks, strokes, blood clots, and death compared to people without the disease.

Cardiology

Does having a prior history of atrial fibrillation increase sudden cardiac death risk?

Yes, a prior history of atrial fibrillation is linked to a higher risk of sudden cardiac death, especially in patients with heart attack or heart failure.

Cardiology

Does finerenone help patients with heart failure with mildly reduced ejection fraction?

Yes, finerenone reduces cardiovascular death and worsening heart failure events in patients with heart failure with mildly reduced ejection fraction, based on a network…

Cardiology

Are SGLT2 inhibitors effective for treating heart failure with mildly reduced ejection fraction?

Yes, SGLT2 inhibitors are effective for treating heart failure with mildly reduced ejection fraction, reducing heart failure hospitalizations and improving outcomes.

Cardiology

Does having pre-eclampsia in the past increase my risk of heart disease later?

Yes, a history of pre-eclampsia is linked to a higher risk of later heart disease, likely due to early blood vessel damage that can be detected years after pregnancy.

Cardiology

How does complex PCI compare to non-complex PCI regarding bleeding risks?

Complex PCI carries a higher risk of major bleeding compared to non-complex PCI, with studies showing a 24% increased hazard for bleeding events.

Cardiology

Do erythropoiesis-stimulating agents help adults with heart failure and anaemia?

ESAs reduce total heart failure hospitalizations and improve hemoglobin and exercise tolerance, but do not lower first hospitalization or mortality risk.

Cardiology

Does going to a hospital with higher cardiac capability help cardiogenic shock patients?

Going to a hospital with higher cardiac capability significantly lowers the risk of death for patients with cardiogenic shock compared to lower-tier facilities.

How this works

We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.

This is not medical advice. Always speak with your own doctor before making decisions about your health.